ABSTRACT
Objective: To describe the clinical characteristics with long-term prognosis in patients with mid-ventricular obstructive hypertrophic cardiomyopathy (MVOHCM). Methods: A total of 66 MVOHCM patients treated in our hospital were retrospectively studied for their morbidity, clinical characteristics and mortality. The cumulative survival rate was calculated by Kaplan-Meier method; the risk factors for cardiac death and cardiovascular events were analyzed by uni- and multivariate Cox proportional hazard model. Results: There were 66 (2.74%) patients suffering from MVOHCM among 2413 patients of hypertrophic cardiomyopathy and the average diagnostic age was (40.16 ± 14.64) years. With (7.30 ± 6.25) years of follow-up study, the cardiovascular mortality was 13.6% and unexplained syncope (HR=13.37, 95% CI: 1.65-114.46, P=0.015) was the independent predictor for cardiovascular death. There were 45.45% (30/66) patients experienced at least 1 time of cardiovascular event and the most frequent one was non-sustained ventricular tachycardia (NSVT); 19.70% (13/66) of patients combined with apical aneurysms, and they were more inclined to experience NSVT. Conclusion: MVOHCM patients usually have unfavorable prognosis with the higher incidence of cardiovascular events, some patients may develop apical aneurysm. The early diagnosis of MVOHCM is important for appropriate treatment.
ABSTRACT
<p><b>OBJECTIVE</b>To compare the clinical features and long-term outcome of patients with midventricular obstructive hypertrophic cardiomyopathy (MVOHCM) and patients with apical hypertrophic cardiomyopathy (AHCM) in China.</p><p><b>METHODS</b>This retrospective study analyzed clinical data of 66 patients with MVOHCM and 263 patients with AHCM from a consecutive single-center cohort consisting of 2 413 patients with HCM. The clinical features, cardiovascular mortality and morbidity were compared between the two groups.</p><p><b>RESULTS</b>Compared with the AHCM, patients in the MVOHCM group was younger and more likely to be symptomatic over a mean follow-up of 7 years. The proportion of MVOHCM and AHCM were 2.7% (66/2 413) and 10.9% (263/2 413) (P < 0.001), respectively, in this cohort. Cardiovascular mortality of the two groups were 13.6% (9/66) and 0.8% (2/263) (P < 0.001), and cardiovascular morbidity of the two groups were 53.0% (35/66) and 14.4% (38/263) (P < 0.001).</p><p><b>CONCLUSION</b>MVOHCM is rarer, but the clinical manifestations and long-term outcomes are worse compared with AHCM in this patient cohort.</p>
Subject(s)
Humans , Cardiomyopathy, Hypertrophic , Retrospective StudiesABSTRACT
Objective: To compare the clinical characteristics and plasma level of N-terminal pro-brain natriuretic peptide (NT-proBNP) between the patients with hypertensive hypertrophic cardiomyopathy in elder age (HHCME) and the patients with hypertensive left ventricular hypertrophy (HTN-LVH). Methods: Our work included 2 groups, HHCME group,n=47 and HTN-LVH group,n=44. Duplex Doppler echocardiography was performed to determine left atrial diameter (LAd), left ventricular end-diastolic dimension (LVEDd), interventricular septal thickness (IVST), left ventricular ejection fraction (LVEF), velocity of early diastolic period (VE) and velocity of end-diastolic period (VA) in mitral valve oriifce. Plasma level of NT-proBNP was measured by ELISA. The above indexes were compared between 2 groups. Results:①Compared with HTN-LVH group, HHCME group presented decreased LVEDd and increased IVST, LVEF, allP0.05.②Plasma level of NT-proBNP was higher in HHCME group,P Conclusion: The plasma NT-proBNP level was higher in HHCME patients than that in HTN-LVH patients which indicated that HHCME patients may have worse prognosis. NT-proBNP might be helpful for differencing HHCME.
ABSTRACT
@#Objective To evaluate the inhibition of urine 11-dH-TXB2 by dihydroxyaluminum aminoacetate-heavy magnesium carbonate-aspirin in Chinese cardiovascular patients after long-term therapy. Methods103 cardiovascular patients were treated with oral doses of dihydroxyaluminum aminoacetate-heavy magnesium carbonate-aspirin tablets (162 mg aspirin) daily for 24 weeks. The Urine 11-dH-TXB2 concentration were measured before and 6, 12, 24 weeks after administration. ResultsThe urine 11-dH-TXB2 concentration were （1840.41±1452.63） pg/ml, （820.01±610.55） pg/ml, （1011.19±1148.12） pg/ml, （1290.82±1425.51） pg/ml before and 6, 12, 24 weeks after administration. The urine 11-dh-TXB2 concentration was higher in 24th week than in 12th weeks and 6th week. ConclusionThe dihydroxyaluminum aminoacetate-heavy magnesium carbonate-aspirin can inhibit the platelet aggregation, which decreased after long-term administration.
ABSTRACT
@#Objective To evaluate the inhibition of urine 11-dH-TXB2 by dihydroxyaluminum aminoacetate-heavy magnesium carbonate-aspirin in Chinese cardiovascular patients after long-term therapy. Methods103 cardiovascular patients were treated with oral doses of dihydroxyaluminum aminoacetate-heavy magnesium carbonate-aspirin tablets (162 mg aspirin) daily for 24 weeks. The Urine 11-dH-TXB2 concentration were measured before and 6, 12, 24 weeks after administration. ResultsThe urine 11-dH-TXB2 concentration were （1840.41±1452.63） pg/ml, （820.01±610.55） pg/ml, （1011.19±1148.12） pg/ml, （1290.82±1425.51） pg/ml before and 6, 12, 24 weeks after administration. The urine 11-dh-TXB2 concentration was higher in 24th week than in 12th weeks and 6th week. ConclusionThe dihydroxyaluminum aminoacetate-heavy magnesium carbonate-aspirin can inhibit the platelet aggregation, which decreased after long-term administration.
ABSTRACT
Objective Dilated cardiomyopathy (DCM) is generally considered to be accompanied by both left and right ventricular dysfunction,but most studies only analyze the left ventricular function. In this study, we evaluated the effect of arotinolol on right ventricular function in patients with DCM. Methods Right ventricular ejection fraction (RVEF) and right ventricular diameter (RVD) were measured by two-dimensional echocardiography (2-DE) in 33 DCM patients; RVEF measured by first-pass radionuclide angiography (FPRA) was compared with that by 2-DE. Results The treatment with arotinolol for one year resulted in a reduction in the right ventricular diameter (baseline, 23.0 ± 8.3 mm vs after one-year treatment, 20.7 ± 5.4 mm; P=0.004 ) and an associated increase in ejection fraction (baseline, 36.9 ± 10.3% vs after one-year treatment, 45.8 ± 9.6%; P ＜ 0.001 ); there is a high correlation between the 2-DE method and radionuclide ventriculographic method. The correlation coefficient is 0.933 (P＜0.001). Conclusion Arotinolol therapy could not only improve left ventricular function, but also improve right ventricular function in DCM patients.